Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 24, 2008

Cellular Dynamics International Consolidates Businesses

  • Cellular Dynamics International (CDI) reported the merger of sister companies Stem Cell Products and iPS Cells with CDI. The merged entity will continue to operate as Cellular Dynamics International. 

    According to the company, the merger positions CDI as a leader in the stem cell research tools and personalized bio-banking industries by placing the intellectual property and commercial, research, and production capabilities of the predecessor companies under a unified management team.    

    CDI was founded in 2004 by James Thomson, Craig January, Timothy Kamp, and Igor Slukvin, professors at the University of Wisconsin-Madison. The firm is currently commercializing pluripotent stem cell-derived cardiomyocytes and a variety of other cell types for use by the pharmaceutical industry.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »